The investigational anti–IL-33 antibody lowered exacerbation rates across all blood eosinophil levels, a benefit current COPD biologics do not offer.
|Articles|July 12, 2004
New glaucoma drug offers convenient once-daily dosing
The FDA recently approved timolol (Istalol, ISTA Pharmaceuticals) ophthalmic solution 0.5% for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The product will be available within the next several months.
Advertisement
Advertisement
Related to this article
This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
A study finds children starting continuous glucose monitoring within a month of diagnosis sustained lower hemoglobin A1C than those who started later.
With obesity, muscle loss, and sleep disorders so prominent in postmenopause, providers are now looking into further expansion of GLP-1 use.
Menopause status and symptoms are inconsistently captured in electronic health records, leaving a gap in care for patients.
As midterm elections approach, the pharmacy industry is backing one of its most meaningful bills yet while the current congressional session wanes.
Data found reduced cardiovascular risk with hormone therapy, particularly among Black women and those starting treatment within 10 years of menopause.
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
3
Menopause Status, Symptoms Remain Inconsistently Documented
4
Early CGMs Results in Better 5-Year Glucose Control in Type 1 Diabetes
5